What question did this study set out to answer?

To investigate the protective efficacy and immunological mechanisms of an adenoviral HER-2 vaccine in mouse models of spontaneous and transplantable mammary carcinomas.

April 1, 2005The Journal of ImmunologyOpen Access

Early Role of CD4+ Th1 Cells and Antibodies in HER-2 Adenovirus Vaccine Protection against Autochthonous Mammary Carcinomas

View Full Paper

Ask AI

Bookmark

To investigate the protective efficacy and immunological mechanisms of an adenoviral HER-2 vaccine in mouse models of spontaneous and transplantable mammary carcinomas.
Immunized BALB-neuT transgenic mice from 6–8 to 19 weeks of age with a recombinant HER-2 adenoviral vaccine and monitored spontaneous mammary tumor onset up to 50 weeks.
Identified critical immune pathways using knockout strains (beta-2-microglobulin, IFN-gamma, B-cell deficient, FcgammaRI/III deficient), antibody-mediated cell depletions (CD4+ and CD8+), and passive antibody transfer.
Vaccination completely prevented spontaneous tumor development through 50 weeks of age, compared to control mice which developed tumors across all 10 mammary glands by 25 weeks.
Induction of anti-HER-2 antibodies, predominantly the IgG2a isotype, was both necessary and sufficient for in vivo protection and in vitro tumor growth inhibition without requiring Fcgamma receptors.
CD4+ T cells were required only transiently for 36–48 hours post-immunization to assist B cells rather than act as effectors, while CD8+ T cells were completely dispensable.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical study demonstrates adenoviral HER-2 vaccination prevents spontaneous mammary tumors in transgenic mice, indicating antibody-mediated protection against HER-2-positive breast cancers.

Cite This Study

Park et al. (2005) studied this question.

synapsesocial.com/papers/6a711d16e5469ee92be1ba4b https://doi.org/10.4049/jimmunol.174.7.4228

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates adenoviral HER-2 vaccination prevents spontaneous mammary tumors in transgenic mice, indicating antibody-mediated protection against HER-2-positive breast cancers.

Early Role of CD4+ Th1 Cells and Antibodies in HER-2 Adenovirus Vaccine Protection against Autochthonous Mammary Carcinomas

Key Points

Discussion

Implication

Cite This Study

Early Role of CD4+ Th1 Cells and Antibodies in HER-2 Adenovirus Vaccine Protection against Autochthonous Mammary Carcinomas

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider